In the field of treatment for digestive diseases, the use of antibacterial drugs is of great importance. The correct and rational application of antibacterial drugs is not only about the efficacy of treatment but also about the safety of patients and the reduction of the production of resistant strains.
First, clear indications of the use of antibacterial drugs are the cornerstone. In digestives, not all gastrointestinal disorders require antibacterial interventions. For example, antibacterial drugs are useless for those who suffer from functional indigestion and non-infective diarrhoea in general, such as those caused by inadequate diet and intestinal stress syndrome, and are then treated mainly by adjusting diets, using gastrointestinal motors or biobacterium. For well-defined bacterial infectious diseases, such as fungus-related gastroenteritis, stomach ulcer, acute bacterial dysentery, cholesterol, cholesterol, etc., the application of antibacterial drugs needs to be considered on a case-by-case basis. In the case of cholesterococcal infections, when the patient is diagnosed with cholesterococcus infection, accompanied by diseases such as stomach mucculitis and ulcer, a combination of proton pump inhibitors and two antibacterial drugs (e.g., Amoxilin, Kracin, etc.) is commonly used, with a total of 10 – 14 days of treatment. Such precision drug-based indicators avoid the abuse of anti-bacterial drugs, reduce unnecessary waste of medical resources and the financial burden on patients, while reducing the risk of drug resistance.
Second, the selection of appropriate antibacterial drugs based on the type of pathogens and on the results of the drug-sensitive tests is essential. There are differences between different parts and diseases in digestive infections. For example, in acute cholesterol, cholesterol, creber, intestinal fungi, etc., common pathogens may be co-infection with multiple aerobics and anaerobics. Prior to the use of anti-bacterial drugs, as far as possible, appropriate specimens (e.g., cholesterol, abdominal fluid, etc.) should be collected for bacterial development and drug sensitivity testing, if conditions permit. However, in clinical practice, experiential medications are often required, for example, because of the urgency of the situation. In the case of empirical drugs, doctors are required to take fully into account the endemic characteristics of the region, the hospital ‘ s pathogen and drug resistance. For example, with regard to community access to acute cholesterol, if local intestinal eschacteria are more sensitive to peptoxin-type drugs, anti-infection treatment can be done with a sepsis-like drug, which is then adjusted to ensure the effectiveness of antibacterial drugs.
Moreover, the rational determination of the dose, the type of agent, the route of delivery and the course of treatment of anti-bacterial drugs are also elements that cannot be overlooked. Overdoses can lead to ineffective treatment and overdoses can increase the risk of adverse drug reactions. For example, for the treatment of anaerobic infections, the oral dose is typically 0.4 – 0.6 g per day, 3 times per day, when a venomic dropting is used, but also in accordance with the medical instructions and relevant guidelines. The choice of a formulation type takes into account the specific circumstances of the patient, such as the choice of an injection for a patient who cannot take an oral drug, and the ease and economy of an oral formulation for a patient with mildly ill infections and a normal gastrointestinal function. In terms of the route of delivery, priority is given to oral treatment for mildly ill infections, while intravenous drugs are used for serious infections or for oral absorption disorders. With regard to the treatment process, in general, for acute infections, after the signs of absconding symptoms, normal body temperature, haemophilia, etc. have returned to normal, there is a need to continue to use drugs for three to five days to ensure the complete elimination of pathogens and prevent recurrence. However, for specific infections, such as chronic cholesterococcal infections, the treatment process is relatively fixed at 10 – 14 days, and excessive or short treatment can affect treatment effectiveness.
In addition, co-medicines have specific applications in digestive antibacterial therapy. As mentioned earlier, the use of four-coederic treatments for cholesterococcal infections is a typical example of joint use. In some cases of severe abdominal co-infection, there is also a common combination of anti-oxygen and anti-aerobic drugs, such as headgills, in association with americium or onitrogen, to expand the antibacterial spectrum and enhance antibacterial effects through the complementarity of different antibacterial mechanisms. Joint drug use, however, must be carefully weighed against pros and cons and avoid drug interactions leading to increased adverse reactions or reduced efficacy.
In digestive clinical practice, health-care personnel should continuously improve their own professional literacy, follow up on the development of anti-bacterial drug application guidelines and research, taking into account a combination of different aspects, from drug indications, drug selection, drug delivery programmes to joint use, to ensure the rational application of anti-bacterial drugs in digestive medicine, to provide safer, effective and accurate medical care for patients and to contribute to curbing anti-bacterial drug resistance.
